fda semaglutide compounding enforcement october 2025 Drug compounders sue over declaration ending Wegovy shortage fda compounding semaglutide enforcement october

However, phentermine carries its own risks and is typically only approved for short-term use, making direct comparison complicated

Results from these rigorous clinical trials will be essential to determine whether GLP-1 medications have a legitimate role in addiction treatment and to identify which patient populations might benefit most

Monitor renal function when initiating or escalating doses of this therapeutic drug in patients with renal impairment

GLP-1 medications create a different rhythm for hunger

Here's the honest picture: it's based on a real, powerful body chemical, it's not approved for the way people use it, and it carries genuine risks that make it different from the 'gentler' peptides

Protects the fragile eye area